Basic Information
The company has developed a highly sensitive, next-generation sequencing-based system to detect cancer mutations in minute concentrations of cell-free DNA (cfDNA) circulating in the blood. The company's technology overcomes significant challenges associated with utilizing the information contained in cfDNA by integrating proprietary methods.
AccuraGen, Inc.
United States of America
less than 15 people
January 01, 2013
--